BCV
RNAM

Banque Cantonale Vaudoise’s Avidity Biosciences RNAM Stock Holding History

Banque Cantonale Vaudoise’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,600
Closed -$45K – 1113
2020
Q3 		$45K Buy
+1,600
New +$46.2K ﹤0.01% 917

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Banque Cantonale Vaudoise's RNAM Position: Q4 2020 in Review

Banque Cantonale Vaudoise sold out of Avidity Biosciences (RNAM) in Q4 2020, closing a stake of 1,600 shares — an estimated $45K sold.

Banque Cantonale Vaudoise first reported a position in RNAM in Q3 2020 and held it in 1 quarter. The position peaked at $45K in Q3 2020. 82 funds tracked by Wall St. Rank hold RNAM as of Q4 2020.

  • Banque Cantonale Vaudoise reported no remaining Avidity Biosciences position as of Q4 2020 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 1,600 Avidity Biosciences shares in Q4 2020, an estimated $45K.
  • Banque Cantonale Vaudoise first reported a position in Avidity Biosciences in Q3 2020 and held it in 1 quarter.
  • Banque Cantonale Vaudoise's Avidity Biosciences position peaked at $45K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2020.

Based on Banque Cantonale Vaudoise's 13F filing for Q4 2020, filed 5 Feb 2021.